The PLASMIC score is a recently described clinical scoring algorithm that rapidly assesses the probability of severe ADAMTS13 deficiency among patients presenting with microangiopathic hemolytic anemia.
Costs for ADAMTS13 test are rising rapidly. Practice patterns vary widely, with most centres relying solely on clinician judgment to determine which patients receive ADAMTS13 testing and undergo TPE.
We hypothesized that a diagnostic and management algorithm based on the PLASMIC score would minimize unnecessary testing and TPE procedures and yield significant cost savings by facilitating the early identification of patients with iTTP.Dr. Benjamin P Geisler, MD, MPH, FACP, MRCP (London)